Insilico Medicine's leadership to address key challenges in AI drug discovery at BIO Convention

May 23 2024Insilico Medicine Leadership from clinical stage artificial intelligence -powered drug discovery company Insilico Medicine will attend the BIO International Convention in San Diego June 3-6 and present on key issues facing AI drug discovery.

At the BIO Convention, Insilico can be found at Booth #5657 and will also have a presence at booths for Investissement Québec and Masdar City. The Company's global presence includes headquarters in Boston and Hong Kong, and research and development centers and labs in Montreal, Shanghai, Suzhou, and Abu Dhabi.

On Mon., June 3, 4:15-5:15 p.m., Insilico Vice President and Global Head of AI Platforms Petrina Kamya, PhD, will speak on the panel "The Use of AI in mRNA: The New Revolution?" discussing the development of new AI models as powerful technologies that enable therapeutic advances in fields such as infectious disease, oncology, and clinical trials. She'll be joined by Mathieu Blanchette, director of McGill University; Christian Barrow, executive director of J.P.

On Tues., June 4, 11am-12pm, Insilico founder and CEO Alex Zhavoronkov, PhD, will speak on the panel "AI's Trial by Fire: Experimental Validation in Drug Discovery," discussing how AI is transforming drug discovery and how rigorous experimental validation is bridging the gap between AI's predictions and its real-world applications.

Related StoriesInsilico Medicine is a pioneer in using generative AI for drug discovery and development. The Company first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal in 2016. Then, Insilico developed and validated multiple approaches and features for its generative adversarial network -based AI platform and integrated those algorithms into the commercially available Pharma.

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeuticClosed Loop Medicine Ltd, a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, and Pharmanovia, a global pharmaceutical company that commercializes novel medicines and revitalizes, extends and expands the lifecycle of established medicines, today announced...
Source: NewsMedical - 🏆 19. / 71 Read more »

Insilico and NVIDIA unveil new LLM transformer for solving biological and chemical tasksIn a new paper, researchers from clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine ('Insilico'), in collaboration with NVIDIA, present a new large language model (LLM) transformer for solving biological and chemical tasks called nach0.
Source: NewsMedical - 🏆 19. / 71 Read more »